ELCC

Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates

Retrieved on: 
Wednesday, May 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Pfizer, Investment, NMPA, Pancreatic cancer, Schizophrenia, ASCO, HKT, Ovarian cancer, AstraZeneca, ELCC, Lung cancer, METIS, Food, CER, Genmab, Roche, GIST, CABP, Psoriasis, BLA, Bristol Myers Squibb, NSCLC, Psychosis, HKEX, NRDL, Safety, SCLC, Research and development, ABSSSI, Marketing, BMS, Clinical trial, Bronchopneumonia, GMG, TED, KarXT, Nivolumab, NDA, Stromal cell, MAA, Carcinoma, Administration, ADS, Patient, Society, Annual general meeting, Sanofi, Growth, Pharmaceutical industry

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates.

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates.
  • “Our first quarter results demonstrate strong commercial execution and pipeline progress across our potential first- and best-in-class product portfolio,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab.
  • In March 2024, Zai Lab presented findings from preclinical studies highlighting the therapeutic potential of ZL-1310 at the European Lung Cancer Congress (ELCC) 2024.
  • Zai Lab to initiate a global Phase 2 study in mild-to-moderate chronic plaque psoriasis in the second quarter of 2024.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doctor of Philosophy, PFS, Paranal Observatory, Table, License, Summit, Investment, ELCC, Progression-free survival, Research, Intraparenchymal hemorrhage, Immunotherapy, Trial of the century, Webcast, Cohort, Forecasting, PD-1, NGS, TKI, Patient, GRAIL, Brain, SMMT, Neoplasm, EGFR, VEGF, GAAP, Royal institute, Neuro, Lung cancer, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
  • In January 2024, followed by a presentation at ELCC 2024 in March 2024, Akeso announced updates from its Phase II AK112-201 trial data.
  • Also at ELCC 2024, Summit and Akeso highlighted promising ivonescimab Phase II data in NSCLC patients with brain metastases.
  • Operating cash outflow for the three months ended March 31, 2024 and 2023 was $30.1 million and $13.1 million, respectively.

PowerGEM, LLC Acquires Astrapé Consulting

Retrieved on: 
Tuesday, April 30, 2024
Environment, Technology, Consulting, Utilities, Professional Services, Alternative Energy, Sustainability, Software, Energy, Weather, Electricity, Transport, Consultant, Accreditation, Acquisition, Ageing, ELCC

PowerGEM, LLC, a leading provider of transmission reliability modeling, market analysis software and technical services for the electric power industry, has acquired Astrapé Consulting, a leader in resource adequacy for reliably managing the transition to clean energy.

Key Points: 
  • PowerGEM, LLC, a leading provider of transmission reliability modeling, market analysis software and technical services for the electric power industry, has acquired Astrapé Consulting, a leader in resource adequacy for reliably managing the transition to clean energy.
  • Astrapé also works with some of the largest power system operators and utilities.
  • “The software and services of PowerGEM and Astrapé will help customers analyze and plan for all these factors to deliver reliable, clean and affordable power for future generations.
  • Astrapé was represented by Maynard Nexsen as legal counsel and Way Ray Shelton as financial advisor.

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Retrieved on: 
Friday, March 22, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, SMMT, Intraparenchymal hemorrhage, Sun, EGFR, Central European Time, Metastasis, ELCC, Progression-free survival, Anaplastic lymphoma kinase, Constipation, Brain, Drug, HKEX, Safety, Anemia, Phase, Summit, TKI, Time in Europe, PFS, ALK, Pharmaceutical industry

The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.

Key Points: 
  • The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.
  • This analysis consisted of the 35 patients with advanced or metastatic NSCLC who had asymptomatic brain metastases at baseline; 28 patients were treated with ivonescimab plus chemotherapy in AK112-201, and seven patients were treated with monotherapy ivonescimab in AK112-202.
  • Patients across both cohorts experienced an intracranial response rate of 34%, and eight patients (23%) experienced a complete response by RANO criteria.
  • The most frequent TEAEs were anemia and decreased neutrophil counts in squamous patients and anemia and constipation in non-squamous patients.

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, SMMT, Sun, EGFR, Central European Time, ELCC, NSCLC, Anaplastic lymphoma kinase, Drug, HKEX, Safety, Phase, Summit, TKI, Time in Europe, ALK, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic.
  • Two posters featuring updated ivonescimab data will be displayed on Friday, March 22 from 12:00 to 12:45pm Central European Time.
  • The first poster, “Intracranial Activity of Ivonescimab Alone or in Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases” includes data from patients with asymptomatic brain metastases at baseline.
  • These patients were enrolled in either AK112-202 (NCT04900363), in which ivonescimab is delivered as monotherapy, or AK112-201 (NCT04736823), in which ivonescimab is delivered in combination with platinum doublet chemotherapy, both of which are Phase II clinical trials for patients with advanced or metastatic NSCLC.

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cell proliferation, Development, Growth, Apoptosis, ELCC, Carcinoma, Partnership, Patient, Neoplasm, Bystander effect, Tumor microenvironment, IND, CDX, Conjugation, PDX, DLL3, HKEX, ADC, SCLC

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310, the company’s global next-generation antibody-drug conjugate (ADC) program.

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310, the company’s global next-generation antibody-drug conjugate (ADC) program.
  • ZL-1310 is a novel and promising ADC within the Zai Lab global oncology R&D pipeline, targeting the Delta-like ligand 3 (DLL3), a validated therapeutic target in the treatment of small cell lung cancer (SCLC).
  • Zai Lab entered a partnership and exclusive worldwide license agreement with MediLink in April 2023.
  • Subsequently, in January 2024, Zai Lab initiated a global Phase 1 study of ZL-1310 in patients with relapsed and refractory SCLC who have progressed after platinum-based treatment.

RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson's ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer

Retrieved on: 
Monday, March 18, 2024
Abstract, Lung cancer, EGFR, Neoplasm, ELCC, NSCLC, Science, Progression-free survival, Patient, Amivantamab, Drug, Johnson & Johnson, TTD, PAPILLON, FDA, Pharmaceutical industry

PRAGUE, March 18, 2024 /PRNewswire/ -- Johnson & Johnson announced today that new data will be featured at this year's European Lung Cancer Congress (ELCC) taking place from March 20 to 23 in Prague, Czech Republic, highlighting the Company's commitment to transform the treatment of lung cancer through the ongoing study of RYBREVANT® (amivantamab)-based regimens in the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Key data to be featured in four mini-oral presentations include results from an exploratory analysis from the Phase 3 MARIPOSA study evaluating the effect of RYBREVANT® dose interruptions on clinical outcomes, new results confirming the recommended dose for monthly subcutaneous administration of amivantamab from the Phase 1b PALOMA study, and post-progression analyses from the pivotal PAPILLON and MARIPOSA-2 studies, which aim to support the differentiated clinical profile of RYBREVANT® in the treatment of patients with EGFR-mutated NSCLC.1,2,3,4

Key Points: 
  • "Following recent regulatory submissions in the U.S. and Europe, we look forward to advancing our transformative portfolio and bringing novel targeted treatment regimens to patients around the world."
  • "The results presented at ELCC reinforce the role RYBREVANT-based treatment regimens may play in improving the standard of care in EGFR-mutated NSCLC," said Henar Hevia, EMEA Therapeutic Area Lead, Oncology, Solid Tumors, Johnson & Johnson Innovative Medicine.
  • "We have made remarkable progress in advancing the science of NSCLC and will continue to evaluate the full potential of RYBREVANT as a treatment for patients through our comprehensive clinical development program."
  • The complete list of Company-sponsored abstracts follows:

AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NSCLC, Ophthalmology, Senior, New Drug Application, MD, ROS1, HKEX, Patient, CDE, Medicine, ELCC, NDA, NMPA, TKI, Cancer, Priority review, Pharmaceutical industry

This NDA is for taletrectinib as a first-line treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have not previously been treated with ROS1 TKIs.

Key Points: 
  • This NDA is for taletrectinib as a first-line treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have not previously been treated with ROS1 TKIs.
  • In 2023, China’s NMPA accepted taletrectinib’s first NDA and granted Priority Review Designation for adult patients with locally advanced or metastatic ROS1-positive NSCLC who have been previously treated with ROS1 TKIs.
  • Both NDAs in China are based on positive results from the Phase 2 TRUST-I (NCT04395677) trial.
  • “I am pleased this second NDA for taletrectinib has been accepted in China.

Analyze the Clinical Trial Landscape Through the Pharma Competitive Intelligence Monitoring Services by DelveInsight

Retrieved on: 
Thursday, January 18, 2024
Noise, Forecasting, AACR, ASCO, Intelligence, Consultant, ELCC, ESMO, Environment, Conference, ATS, EULAR, IPF, ASH, News, Diagnosis, ERS, Growth

LAS VEGAS, Jan. 18, 2024 /PRNewswire/ -- DelveInsight, a leading pharma competitive intelligence and consulting solutions company, offers dynamic Pharma Competitive Intelligence Monitoring Services. Through this service, clients can easily monitor developmental assets, clinical trials, regulatory milestones, commercial news, and receive high-priority alerts in real time as well as assess updates via an online dashboard. 

Key Points: 
  • LAS VEGAS, Jan. 18, 2024 /PRNewswire/ -- DelveInsight, a leading pharma competitive intelligence and consulting solutions company, offers dynamic Pharma Competitive Intelligence Monitoring Services .
  • Competitive intelligence monitoring enables companies to swiftly adjust to market fluctuations, comprehend patient needs, address developmental challenges, enhance their overall decision-making processes, and leverage competitive advantage.
  • Demonstrating proficiency in Competitive Intelligence Monitoring, DelveInsight assists clients in fortifying their brand's market standing and company's overall positioning, staying abeam of prevailing industry trends.
  • Leverage our Competitive Intelligence Monitoring Services for precise and effective results:
    Monitor competitors extensively; who are in product development, or those already in the market
    Ask for a proposal to find out how DelveInsight's pharma Competitive intelligence monitoring solutions can assist you.

Analyze the Clinical Trial Landscape Through the Pharma Competitive Intelligence Monitoring Services by DelveInsight

Retrieved on: 
Thursday, January 18, 2024
Noise, Forecasting, AACR, ASCO, Intelligence, Consultant, ELCC, ESMO, Environment, Conference, ATS, EULAR, IPF, ASH, News, Diagnosis, ERS, Growth

LAS VEGAS, Jan. 18, 2024 /PRNewswire/ -- DelveInsight, a leading pharma competitive intelligence and consulting solutions company, offers dynamic Pharma Competitive Intelligence Monitoring Services. Through this service, clients can easily monitor developmental assets, clinical trials, regulatory milestones, commercial news, and receive high-priority alerts in real time as well as assess updates via an online dashboard. 

Key Points: 
  • LAS VEGAS, Jan. 18, 2024 /PRNewswire/ -- DelveInsight, a leading pharma competitive intelligence and consulting solutions company, offers dynamic Pharma Competitive Intelligence Monitoring Services .
  • Competitive intelligence monitoring enables companies to swiftly adjust to market fluctuations, comprehend patient needs, address developmental challenges, enhance their overall decision-making processes, and leverage competitive advantage.
  • Demonstrating proficiency in Competitive Intelligence Monitoring, DelveInsight assists clients in fortifying their brand's market standing and company's overall positioning, staying abeam of prevailing industry trends.
  • Leverage our Competitive Intelligence Monitoring Services for precise and effective results:
    Monitor competitors extensively; who are in product development, or those already in the market
    Ask for a proposal to find out how DelveInsight's pharma Competitive intelligence monitoring solutions can assist you.